| Symbol | ABUS |
|---|---|
| Name | ARBUTUS BIOPHARMA CORP |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | Pharmaceutical Preparations |
| Address | 701 VETERANS CIRCLE, WARMINSTER, PA 18974 |
| Telephone | 604-419-3200 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | None |
(86% Positive) ARBUTUS BIOPHARMA CORP (ABUS) Provides Update on imdusiran for several benefits
Read moreArbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
Read moreNew Form DEFA14A - Arbutus Biopharma Corp <b>Filed:</b> 2026-04-14 <b>AccNo:</b> 0001140361-26-014624 <b>Size:</b> 4 MB
Read moreNew Form DEF 14A - Arbutus Biopharma Corp <b>Filed:</b> 2026-04-14 <b>AccNo:</b> 0001140361-26-014623 <b>Size:</b> 6 MB
Read moreNew Form SCHEDULE 13D/A - Arbutus Biopharma Corp <b>Filed:</b> 2026-04-13 <b>AccNo:</b> 0000921895-26-000973 <b>Size:</b> 28 KB
Read more(30% Negative) ARBUTUS BIOPHARMA CORP (ABUS) Reports Q1 2026 Financial Results
Read moreArbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Read moreGenevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
Read moreNew Form SCHEDULE 13G/A - Arbutus Biopharma Corp <b>Filed:</b> 2026-02-17 <b>AccNo:</b> 0001011438-26-000149 <b>Size:</b> 11 KB
Read moreNew Form SCHEDULE 13G/A - Arbutus Biopharma Corp <b>Filed:</b> 2026-02-11 <b>AccNo:</b> 0000895421-26-000041 <b>Size:</b> 12 KB
Read more